226701-59-3 Usage
Uses
Used in Pharmaceutical Synthesis:
Benzonitrile, 4,5-diamino-2-fluoro(9CI) is used as an intermediate in the synthesis of more complex pharmaceutical and biologically active compounds. Its unique structure allows for the development of molecules with specific therapeutic properties.
Used in Inhibitor Development:
Benzonitrile, 4,5-diamino-2-fluoro(9CI) is utilized in the preparation of Indazoles, which are inhibitors of Tpl2 kinase. Tpl2 kinase is a protein involved in various cellular processes, and its inhibition can have therapeutic implications in treating certain diseases.
Used in the Development of Therapeutic Agents:
The compound is also employed in the development of therapeutic agents targeting specific biological pathways. Its unique structure enables the creation of molecules with potential therapeutic applications in various medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 226701-59-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,6,7,0 and 1 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 226701-59:
(8*2)+(7*2)+(6*6)+(5*7)+(4*0)+(3*1)+(2*5)+(1*9)=123
123 % 10 = 3
So 226701-59-3 is a valid CAS Registry Number.
226701-59-3Relevant academic research and scientific papers
Complement pathway modulators and uses thereof
-
Paragraph 1122, (2013/11/19)
The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors
Mackman, Richard L.,Hui, Hon C.,Breitenbucher,Katz, Bradley A.,Luong, Christine,Martelli, Arnold,McGee, Danny,Radika, Kesavan,Sendzik, Martin,Spencer, Jeffrey R.,Sprengeler, Paul A.,Tario, James,Verner, Erik,Wang, Jing
, p. 2019 - 2022 (2007/10/03)
The development of potent and selective urokinase-type plasminogen activator (uPA) inhibitors based on the lead molecule 2-(2-hydroxy-3-ethoxyphenyl)-1H-benzimidazole-5-carboxamidine (3a) is described.
Compounds and compositions as anticoagulants
-
, (2008/06/13)
The present invention relates to novel biheterocyclic derivatives which are factor Xa inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making.
